Resonance Specialties Shares Soar 20% After Financial Results

Key numbers

PE Ratio	15.95xSector 34.09x
1-Year Return	105.2%CMP ₹200.5
Promoter Holding	54.25%Zero Pledge
RSI	60.11Stable Zone

Key highlights

• Net Profit surged 400% year-on-year to ₹8.5 crore from ₹1.7 crore in Q2 FY26
• Revenue from operations grew 60% to ₹34.3 crore compared to ₹21.5 crore in the same period last year
• Operating margins expanded sharply to 32.3%, up from 10.5% in the year-ago quarter
• International segment revenue reached ₹49.31 crore for H1 FY27, more than doubling from ₹22.75 crore YoY
• Sequential performance remained strong with PAT rising 49.1% from ₹5.7 crore in Q1 FY27

Margin Expansion and Profitability Growth

Resonance Specialties delivered a robust financial performance in the second quarter of FY27, characterized by a substantial jump in profitability. The company reported a net profit of ₹8.5 crore, a massive 400% increase from the ₹1.7 crore reported in the corresponding quarter of the previous year. This bottom-line growth was supported by a 60% increase in revenue from operations, which reached ₹34.3 crore.

A critical factor in this performance was the dramatic expansion of operating margins, which improved from 10.5% to 32.3% year-on-year. Sequentially, the company maintained its momentum, with PAT rising 49.1% from the ₹5.7 crore recorded in the June quarter.

International Markets Drive Half-Year Performance

• Revenue from outside India climbed to ₹49.31 crore for April-September 2026, up from ₹22.75 crore in the previous year
• Domestic revenue from the India segment saw a slight contraction to ₹17.56 crore for the half-year period
• The company continues to operate under a single primary reportable business segment: Chemical Manufacturing
• Total comprehensive income for the quarter stood at ₹8.4 crore after accounting for actuarial losses
• Cash and cash equivalents at the end of the half-year improved to ₹0.26 crore compared to the previous year-end

Acquisition and Capacity Expansion Strategy

The strong quarterly numbers come as Resonance Specialties moves toward the final stages of its slump-sale acquisition of Kaygee Laboratories' Mandideep manufacturing facility. The transaction, valued at ₹29.98 crore, was approved by shareholders in September 2026 and has a target completion date of November 30, 2026. This move is expected to enhance the company's production capabilities in the specialty chemicals sector.

Amidst this expansion, CRISIL reaffirmed the company's bank facility rating at 'CRISIL BBB-/Stable' in August 2026, citing its established market position. The company currently trades at a P/E of 15.95, significantly below the industry average of 38.25.

What to watch next

• Completion of Mandideep manufacturing facility acquisition, scheduled for November 30, 2026
• Operational integration and production ramp-up at the newly acquired Kaygee Laboratories site
• Third-quarter results announcement expected in early February 2027
• Monitoring export demand sustainability given the significant growth in the 'Outside India' segment

Resonance Specialties · financial snapshot

Share price	₹200.5
Market capitalisation	₹231.46 Cr
Revenue (annual)	₹90.25 Cr
Net profit (annual)	₹10.40 Cr
Revenue (latest quarter)	₹32.58 Cr+33.12% vs previous quarter
Net profit (latest quarter)	₹5.74 Cr+24.99% vs previous quarter
P/E (TTM)	15.95×Sector 34.09×
Promoter holding	54.25%0.00% QoQ
FII holding	0%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.